Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan
Shots:
- Alumis & Kaken have partnered to develop, manufacture, & market ESK-001 for dermatology in Japan, with an option to expand into rheumatology & GI diseases
- As per the deal, Kaken will handle development, approval & marketing of ESK-001 in Japan in exchange for $40M upfront & near-term co-development costs, with ~$140M in milestones & field option payments, plus net sales-based tiered royalties. Global development will be partially co-funded, with Alumis retaining rights in other regions
- ESK-001 is being investigated in P-IIb trial for SLE & P-III (ONWARD) program for 24wks., incl. 2 P-III (ONWARD1 & 2) trials for mod. to sev. Plaque PsO, after which pts could opt for an LTE study
Ref: Globenewswire | Image: Alumis & Kaken
Related News:- Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop Novel Therapies for Immune-mediated Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
